Annual report pursuant to Section 13 and 15(d)

Selected Quarterly Financial Data

v3.7.0.1
Selected Quarterly Financial Data
12 Months Ended
Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]  
Selected Quarterly Financial Data (Unaudited)

Quarterly financial information for fiscal 2016 and 2015 are presented in the following table, in thousands, except per share data:

 

    For the Quarter Ending
    March 31   June 30   September 30   December 31
2016:                                
Lymphoseek sales revenue   $ 3,783     $ 4,232     $ 6,690     $ 2,332  
Lymphoseek license revenue     254       246       1,296       —    
Grant and other revenue     686       917       511       1,023  
Gross profit     4,188       4,834       7,575       3,076  
Operating expenses     6,756       5,414       4,217       5,509  
Operating income (loss)     (2,568 )     (580 )     3,358       (2,433 )
Net loss attributable to common stockholders     (3,686 )     (6,681 )     (59 )     (3,883 )
Basic and diluted net loss per share (1)   $ (0.02 )   $ (0.04 )   $ (0.00 )   $ (0.03 )
                                 
2015:                                
Lymphoseek sales revenue   $ 1,835     $ 1,964     $ 2,953     $ 3,503  
Lymphoseek license revenue     83       250       550       250  
Grant and other revenue     190       654       477       541  
Gross profit     1,659       2,535       3,522       3,778  
Operating expenses     9,475       6,346       7,845       6,379  
Operating loss     (7,816 )     (3,811 )     (4,323 )     (2,601 )
Net loss attributable to common stockholders     (7,337 )     (9,691 )     (8,071 )     (2,510 )
Basic and diluted net loss per share (1)   $ (0.05 )   $ (0.06 )   $ (0.05 )   $ (0.02 )

 

(1) Net loss per share is computed independently for each of the quarters presented. Therefore the sum of the quarterly per-share calculations will not necessarily equal the annual per share calculation.